Illumina (NASDAQ:ILMN) Reaches New 12-Month High – What’s Next?

Illumina, Inc. (NASDAQ:ILMN)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $177.76 and last traded at $176.8650, with a volume of 705216 shares traded. The stock had previously closed at $164.93.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research note on Wednesday. Guggenheim increased their target price on shares of Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Thursday, May 14th. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Citigroup upped their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $143.56.

Illumina Stock Performance

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a market cap of $26.88 billion, a price-to-earnings ratio of 32.30, a price-to-earnings-growth ratio of 3.28 and a beta of 1.50. The company has a fifty day moving average price of $148.74 and a two-hundred day moving average price of $137.38.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company earned $0.97 earnings per share. Illumina’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 5.21 EPS for the current year.

Insider Buying and Selling at Illumina

In related news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares in the company, valued at approximately $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 in the last ninety days. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Hedge funds have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its position in shares of Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after purchasing an additional 79 shares during the period. HighPoint Advisor Group LLC lifted its stake in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares in the last quarter. Meeder Advisory Services Inc. increased its position in shares of Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after acquiring an additional 85 shares in the last quarter. Toronto Dominion Bank increased its position in shares of Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares in the last quarter. Finally, Panagora Asset Management Inc. raised its holdings in shares of Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.